We observe a clear bias towards well-known candidate genes like SNCA for PD and MBP for MS; in order to overcome this bias, dedicated effort towards investigating the role of the new candidate genes and related bioprocesses is required. This evidence concerns the gene MBP and myeloid sarcoma.